Jacobson Pharma Announces FY2022 Interim Results

Published by
ACN Newswire

Robust Growth of 11.6% in Generics Business Amidst the PandemicConfident about Sustaining Strong Growth MomentumDeclares Interim Dividend of HK1.2 Cents Per ShareA 50% Growth Compared to FY2021 InterimHONG KONG, Nov 26, 2021 – (ACN Newswire) – Jacobson Pharma Corporation Limited (Jacobson Pharma or the Company; HKG: 2633), a leading company engaging in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the interim results of the Company and its subsidiaries (collectively the Group) for the six month…

Read More

Leave a Reply